Impact of Body Weight Dynamics Following Intentional Weight Loss on Fracture Risk: Results from The Action for Health in Diabetes Study

Kristen M Beavers,1 Rebecca H Neiberg,2 Karen C Johnson,3 C Hunter Davis,1 Ramon Casanova,2 Ann V Schwartz,4 Carolyn J Crandall,9 Cora E Lewis,6 Xavier Pi-Sunyer,7 and Stephen B Kritchevsky2; the Look AHEAD Research Group

ABSTRACT

The purpose of this study is to explore the impact of body weight change following intentional weight loss on incident fracture and bone mineral density (BMD) in overweight and obese adults with diabetes. A total of 1885 individuals with type 2 diabetes (baseline age: 58.5 ± 6.7 years, 58% women, body mass index: 35.7 ± 6.0 kg/m²) who participated in the Look AHEAD study and lost any weight 1 year after being randomized to an intensive lifestyle intervention were assessed. Body weight was measured annually and participants were categorized as weight regainers, weight cyclers, or continued losers/maintainers based on a ±3% annual change in weight from year 1 to year 4. Adjudicated overall fracture incidence was captured from years 4 through 13 (median follow-up duration 11.5 years). Hip and spine BMD was assessed in a subset of participants at baseline, year 4 (n = 468), and year 8 (n = 354), using dual-energy X-ray absorptiometry. Cox proportional hazards and linear regression models, adjusted for relevant covariates, were performed for fracture and BMD outcomes, respectively. Fifty-eight percent, 22%, and 20% of participants were classified as weight regainers, weight cyclers, and continued losers/maintainers, respectively; and 217 fractures (men n = 63; women n = 154) were recorded during the follow-up period. There were no statistically significant differences in total incident fracture rates for weight gainers (HR [95% CI]: 1.01 [95% CI, 0.71 to 1.44]) or weight cyclers (HR [95% CI]: 1.02 [95% CI, 0.68 to 1.53]) when compared to continued losers/maintainers (p = 0.99). Similarly, follow-up BMD estimates did not significantly vary by weight pattern group, although consistent trends for lowered BMD in the hip region were noted for continued losers/maintainers and weight cyclers compared with weight regainers. Patterns of weight change in the 3 years following 1 year of intentional weight loss were not associated with subsequent fracture or significantly reduced BMD in this cohort of overweight and obese adults with type 2 diabetes. © 2018 The Authors. JBMR Plus is published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.

KEY WORDS: WEIGHT CHANGE; WEIGHT VARIABILITY; FRACTURE; BMD; TYPE 2 DIABETES

Introduction

Osteoporotic fracture is a serious and costly clinical problem associated with type 2 diabetes.1,2 Overweight or obese individuals with diabetes are often prescribed weight loss to improve glycemic control,2 yet weight loss may further augment fracture risk.3 Indeed, recent results from the Look AHEAD study suggest 6% to 9% weight loss achieved and maintained over nearly a decade is associated with significantly reduced bone mineral density (BMD)4,5 and increased risk of hip, pelvis, and upper arm fracture.6 Data also suggest that bone mass is not recovered when lost weight is regained,7,8 raising concern about the long-term impact of repeated weight loss attempts on bone health. Given the well-known recidivism of obesity,9 surprisingly little is known about the effect of weight regain or weight cycling on incident fracture risk. Limited observational data do link weight variability10,11 and self-reported weight cycling12,13 with higher fracture incidence; yet weight loss in overweight adults with type 2 diabetes is often recidivistic,14 raising concern about the long-term impact of repeated weight loss attempts on bone health.
Materials and Methods

The Look AHEAD Study was a multicenter, randomized controlled trial designed to determine whether intentional weight loss reduces cardiovascular morbidity and mortality in overweight individuals with type 2 diabetes. The study was approved by local Institutional Review Boards and all participants provided informed consent. Details on the study design and baseline characteristics have previously been published, along with treatment effects on BMD and fracture. The primary analysis of this work includes 1885 (of 2570) Intensive Lifestyle Intervention (ILI) participants who were successful at losing any weight during the first year of the study (n = 2290) and had at least two follow-up weights (excluded n = 301), no fractures prior to year 4 (excluded n = 77), and non-missing covariate data (excluded n = 27).

Exposure assessment: weight patterns

Weight was measured annually by certified clinic staff, masked to intervention assignment, using a Tanita BWB 800 digital scale (Tanita, WIllobrook, IL). Based on the first 3 years of follow-up (years 1 through 4), participants were classified into three categories: (i) weight regainers, (ii) weight cyclers, and (iii) continued losers/maintainers, using patterns previously employed in the Look AHEAD study and a clinically meaningful ±3% weight change threshold.

Primary outcome assessment: incident fracture

Centrally adjudicated incident fractures included in this analysis occurred between year 4 and the end of the Look AHEAD-Continuation phase, with maximum follow-up time of 13.2 years (median, 11.5 years). As described, overall fracture included adjudicated hand (not finger), lower arm or wrist, elbow, upper arm, shoulder, clavicle, spine or back, tailbone, pelvis, hip, upper leg, knee, lower leg or ankle, and foot (not toe); we also examined a composite variable for the first occurrence of hip, pelvis, or upper arm fracture (not including clavicle or scapula).

Secondary outcome assessment: change in regional BMD

Total hip, femoral neck, and lumbar spine BMD were assessed at five of the 16 Look AHEAD clinical sites using Hologic fan beam densitometers (DXA), as described. The BMD study sample was derived using the same inclusion criteria described for the incident fracture sample, and limited to participants with baseline and year 4 (n = 468) or year 8 (n = 354) regional DXA scans.

Covariates

Self-reported characteristics (ie, age, gender, race/ethnicity, smoking status, and alcohol consumption) and medical history were assessed using standardized questionnaires. Height was measured in duplicate using a stadiometer and body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Participants brought current prescription medications to update medication records, with bone negative medications defined as: loop diuretics, selective serotonin reuptake inhibitors (SSRIs), thyroid hormones, oral steroids such as prednisone, tricyclic antidepressants, and thiazolidinediones (TZDs); and bone positive medications defined as: androgens (anabolic steroids), calcium, antacids containing calcium, and antiresorptive agents such as bisphosphonates, calcitonin nasal spray, estrogens, and selective estrogen receptor modulators (SERMs). Fasting blood specimens were analyzed by the Central Biochemistry Laboratory (Northwest Lipid Research Laboratories, University of Washington, Seattle, WA, USA) using standardized laboratory procedures for measuring glycated hemoglobin (HbA1c). Depressive symptoms were assessed using the Beck Depression Inventory (BDI; score range 0 to 63), with higher scores indicating more symptoms of depression.

Statistical methods

Descriptive statistics were calculated overall and by weight pattern classification at baseline. Cox proportional hazards models, both unadjusted and adjusted for relevant baseline covariates (including: age category, gender, race, BMI category, bone-positive medication use, and bone-negative medication use, history of arthritis, HbA1c, smoking status, alcohol consumption, diabetes duration, and BDI score) were performed for incident overall and hip, pelvis, or upper arm fracture outcomes. Because fracture risk is elevated in older women, a formal test of interaction between age, gender, and weight pattern category was conducted to inform whether stratified analyses should be performed. Differences in hip, femoral neck, and lumbar spine BMD at years 4 and 8 were assessed in a subset of participants using linear regression models, adjusting for the same covariates described above plus baseline value of the outcome, and presented as least square means and standard errors. All statistical analyses were executed using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA).

Results

Participant characteristics

Baseline descriptive characteristics, detailed by group and overall, are presented in Table 1. As shown, average age was 58.5 ± 6.7 years, 58% were female, 64% were white, and BMI was 35.7 ± 6.0 kg/m². Fifty-eight percent, 22% and 20% of participants were classified as weight regainers, weight cyclers, and continued losers/maintainers, respectively. On average, by the year 4 visit, regainers gained 8.3 ± 5.5 kg, weight cyclers gained 1.1 ± 7.0 kg, and continued losers/maintainers lost 2.9 ± 6.0 kg from the year 1 weight. Weight cyclers were more likely to be between the ages of 50 and 59 years, female, Hispanic, and using bone-positive medications, than other categories (all p < 0.02). Participants in the DXA analyses were more likely to be female (p < 0.01), of ethnic minority (p < 0.01), and slightly younger (p = 0.05) when compared to the main analysis sample; however, the distribution of weight pattern categories within the DXA subset was similar to the larger study sample (data not shown).
Association between weight patterns and incident fracture

Over a total of 11.5 years of follow-up, 217 fractures (men \( n = 63 \); women \( n = 154 \)) were recorded overall. Figure 1 presents Kaplan-Meier curves of incident overall fracture by weight pattern category. There were no statistically significant differences in total incident fracture rates for weight regainers (HR [95% CI]: 1.01 [95% CI, 0.71 to 1.44]) or weight cyclers (1.02 [95% CI, 0.68 to 1.53]) when compared to continued losers/maintainers (\( p = 0.99 \)). Similar results were observed for incident hip, pelvis, or upper arm fracture (data not shown). The interaction between age, gender, and weight pattern category was not significant (\( p = 0.75 \)), thus stratified analyses were not pursued.

Table 1. Baseline Characteristics Overall and by Weight Pattern Category Among Look AHEAD Participants Randomized to Intensive Lifestyle Intervention Who Lost Weight in the First Year

| Characteristic                             | Overall    | Weight regainer | Weight cycler | Continued loser or maintainer | \( p \) |
|--------------------------------------------|------------|-----------------|---------------|-------------------------------|--------|
| Total, \( n \) (%)                         | 1885 (100) | 1086 (58)       | 418 (22)      | 381 (20)                      | 0.02   |
| Age category (years), \( n \) (%)           |            |                 |               |                               |        |
| <50 years                                  | 205 (11)   | 117 (11)        | 52 (12)       | 36 (9)                        |        |
| 50–59 years                                | 890 (47)   | 495 (46)        | 223 (53)      | 172 (45)                      |        |
| 60–69 years                                | 669 (35)   | 407 (37)        | 121 (29)      | 141 (37)                      |        |
| 70+ years                                  | 121 (6)    | 67 (6)          | 22 (5)        | 32 (8)                        |        |
| Female gender, \( n \) (%)                 |            |                 |               |                               | <0.01  |
| African American                           | 305 (16)   | 162 (15)        | 65 (16)       | 78 (20)                       |        |
| Hispanic                                   | 229 (12)   | 119 (11)        | 61 (15)       | 49 (13)                       |        |
| White                                      | 1214 (64)  | 745 (69)        | 259 (62)      | 210 (55)                      |        |
| Other                                      | 137 (7)    | 60 (6)          | 33 (8)        | 44 (12)                       |        |
| BMI category (kg/m\(^2\)), \( n \) (%)     |            |                 |               |                               | 0.05   |
| 25–27                                      | 59 (3)     | 30 (3)          | 12 (3)        | 17 (4)                        |        |
| 27–30                                      | 251 (13)   | 149 (14)        | 43 (10)       | 59 (15)                       |        |
| 30–35                                      | 675 (36)   | 412 (38)        | 143 (34)      | 120 (32)                      |        |
| 35–40                                      | 486 (26)   | 266 (24)        | 113 (27)      | 107 (28)                      |        |
| 40+                                        | 414 (22)   | 229 (21)        | 107 (26)      | 78 (20)                       |        |
| Bone-negative medication use, \( n \) (%)\(^a\) | 851 (45)   | 493 (45)        | 192 (46)      | 166 (44)                      | 0.77   |
| Bone-positive medication use, \( n \) (%)\(^b\) | 471 (25)   | 261 (24)        | 125 (30)      | 85 (22)                       | 0.03   |
| Presence of arthritis, \( n \) (%)        | 771 (41)   | 426 (39)        | 174 (42)      | 171 (45)                      | 0.15   |
| HbA1c (%), mean ± SD                       | 7.2 ± 1.1  | 7.1 ± 1.1       | 7.3 ± 1.1     | 7.3 ± 1.1                     | <0.01  |
| Smoking status, \( n \) (%)               |            |                 |               |                               | 0.17   |
| Never                                      | 950 (50)   | 533 (49)        | 233 (56)      | 184 (48)                      |        |
| Past                                       | 852 (45)   | 506 (46)        | 168 (40)      | 178 (47)                      |        |
| Present                                    | 83 (5)     | 47 (4)          | 17 (4)        | 19 (5)                        |        |
| Alcohol consumption, \( n \) (%)           |            |                 |               |                               | 0.08   |
| None/week                                  | 1279 (68)  | 720 (66)        | 295 (71)      | 264 (69)                      |        |
| 1–3/week                                   | 358 (19)   | 219 (20)        | 80 (19)       | 59 (15)                       |        |
| 4+/week                                    | 248 (13)   | 147 (14)        | 43 (10)       | 58 (15)                       |        |
| Diabetes duration (years), mean ± SD       | 6.6 ± 6.6  | 6.6 ± 6.6       | 6.4 ± 6.7     | 7.0 ± 6.4                     | 0.36   |
| Beck Depression Inventory score (0–63), mean ± SD | 5.3 ± 5.0 | 5.1 ± 4.9       | 5.7 ± 5.2     | 5.2 ± 4.8                     | 0.14   |

Weight change pattern during the first 4 years of follow-up.

SSRI = selective serotonin reuptake inhibitor; TZD = thiazolidinedione; SERM = selective estrogen receptor modulator.

\(^a\)Bone-negative medications are defined as: loop diuretics, SSRIs, thyroid hormones, oral steroids such as prednisone, tricyclic antidepressants, and TZDs.

\(^b\)Bone-positive medications are defined as: androgens (anabolic steroids), calcium, antacids containing calcium, and antiresorptive agents such as bisphosphonates, calcitonin nasal spray, estrogens, and SERMs.
values in continued losers/maintainers, weight cyclers, and weight regainers, respectively ($p = 0.21$). No signal was observed for change in lumbar spine BMD (continued losers/maintainers: $+0.033 \pm 0.015 \text{g/cm}^2$, weight cyclers: $+0.018 \pm 0.015 \text{g/cm}^2$, and weight regainer: $+0.023 \pm 0.013 \text{g/cm}^2$; $p = 0.48$).

**Discussion**

There is increasing interest in understanding the skeletal effects of obesity and diabetes, particularly in the context of weight loss. As reported, randomization to an intensive lifestyle intervention, resulting in weight loss for most participants, was associated with modest bone loss$^{10,11}$ and increased risk of fractures occurring at the hip, pelvis, and upper arm.$^{60}$ Here we report that, among those randomized to the lifestyle intervention who lost weight during the first year, patterns of weight change in the subsequent 3 years were not associated with incident fracture or significantly reduced BMD; however, data suggest a trend toward lowered BMD at the hip among continued losers/maintainers and weight cyclers, compared to weight regainers.

We are aware of only four studies examining the effect of weight variability$^{12,13}$ or cycling$^{12,13}$ on fracture risk to date, all of which report positive associations. The earliest reports, examining weight variability (defined using the root mean square error) and incident hip fracture, suggest a 50% to 270% increased risk for those in the highest quartile of weight variability, compared to the lowest. More recent studies led by Søgaard and colleagues$^{12,13}$ extend these findings to weight cycling, demonstrating increased risk of forearm fracture in men$^{12}$ and nonvertebral fracture in women$^{13}$ who self-reported multiple weight loss episodes (ie, $\geq 4$ in men and $\geq 11$ in women). In contrast, relative to continued weight loss or weight loss maintenance, we did not observe an association between a single bout of weight regain or weight cycling on fracture incidence, thereby adding equipoise to a limited evidence base. Certainly, discrepancies may be due to differing definitions used for weight cycling, as well as the lower number of absolute weight cycles possible in our study.

To our knowledge, our study is the first to assess the effect of weight patterns dynamics following intentional weight loss on incident fracture; although the effect of weight change following voluntary weight loss on BMD has been assessed in a handful of studies, some, but not all,$^{18,19}$ studies suggest that the well-described 2% decline in BMD with 10% weight loss continues progressively despite weight loss maintenance,$^{50}$ and does not return with weight regain.$^{74}$ Trends observed in our BMD data are in general agreement with prior reports, although results were nonsignificant. Importantly, if true, these observations suggest that skeletal remodeling is affected by factors other than change in loading forces, and may imply that transient weight loss attempts have lasting catabolic effects on the skeleton.

Strengths of this study include use of objectively measured weights to assess changing weight dynamics following intentional weight loss, as well as adjustment for multiple, relevant covariates. Despite these design strengths, Look AHEAD was not designed to detect differences in incident fracture rates between weight pattern classifications; thus, our analyses may have been underpowered. Certainly, DXA data, which were only available in a subset, are meant to be hypothesis generating, rather than confirmatory. A general limitation in this field of research is the lack of an operational definition for weight cycling. Although we used patterns previously employed in the Look AHEAD study$^{16}$ and a clinically meaningful$^{17}$ weight change threshold, conclusions may differ by weight pattern category definition used. Last, extrapolation of results should be limited to similar populations, particularly with regard to age and disease status.

In conclusion, in this cohort of overweight and obese adults with type 2 diabetes experiencing intentional weight loss over a year, we did not observe a significant association between subsequent patterns of weight change and incident fracture. Overall, findings temper concerns regarding weight cycling following intentional weight loss on fracture risk, at least in the short term, although certainly more work in this area is needed.

**Disclosures**

All authors state that they have no conflicts of interest.

**Acknowledgments**

The Look AHEAD Study was funded by the National Institutes of Health through cooperative agreements with the National Institute of Diabetes and Digestive and Kidney Diseases: DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, and DK56992. Additional funding was provided by the National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; NIH Office of Research on Women’s Health; and the Centers for Disease Control and Prevention. This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. The Indian Health Service provided personnel, medical oversight, and use of facilities. Additional support was received from The Johns Hopkins Medical Institutions Bayview General Clinical Research Center (M01RR02719); the Massachusetts General Hospital...
Mallinckrodt General Clinical Research Center and the Massachusetts Institute of Technology General Clinical Research Center (M01RR01066); the Harvard Clinical and Translational Science Center (RR025758-04); the University of Colorado Health Sciences Center General Clinical Research Center (M01RR00051) and Clinical Nutrition Research Unit (P30 DK48520); the University of Tennessee at Memphis General Clinical Research Center (M01RR0221140); the University of Pittsburgh General Clinical Research Center (GCRC) (M01RR00056), the Clinical Translational Research Center (CTRC) funded by the Clinical & Translational Science Award (UL1 RR024153) and NIH grant (DK 046204); the VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; and the Frederic C. Bartter General Clinical Research Center (M01RR01346). KMB's effort on this project was also supported by a National Institute on Aging grant (K01 AG047921).

Look AHEAD Research Group at End of Continuation

Clinical sites

The Johns Hopkins University: Frederick L. Brancati, MD, MHS1
Universal of Pennsylvania: John M. Jakicic, PhD1

Continuation

Look AHEAD Research Group at End of

University of Minnesota: Robert W. Jeffery, PhD1; Tricia Skarpohl, MA2; John P. Bantle, MD3; J. Bruce Redmond, MD3; Donald Williamson, PhD2; Timothy Church, MD2; Catherine Champagne, PhD, RD; Valerie Myers, PhD; Jennifer Ancereaux, RN; Kristi Rau; Michelle Begnau, LDN, RD, CDE; Barbara Cerniauskas, LDN, RD, CDE; Crystal Duncan, LPN; Helen Guay, LDN, LPC, RD; Carolyn Johnson, LPN, Lisa Jones; Kim Landry; Missy Lingle; Jennifer Peraud; Cindy Puckett; Marisa Smith; Lauren Cox; Monica Lockett, LPN.

The University of Alabama at Birmingham: Cora E. Lewis, MD, MPH1; Sheikilya Thomas, PhD,MPH; Monika Safford, MD3; Andrea Kriska, PhD3; Lewis H. Kuller, MD, DrPH3; Amy D. Rickman, PhD3; Richard S. Crow, MD3; Manami Bhattacharya, MD3; Heather Turgeon, RN, BS, CDE2; Barbara Steiner, BS; Elizabeth McKinney, BSN, RN; Kristi Rau; Michelle Begnau, LDN, RD, CDE; Mary Anne Holowaty, MS, CN; Michelle Horowitz, MS, RD; Les James; Raashi Mantami, MD.

University of Pennsylvania: Thomas A. Wadden, PhD1; Barbara J. Maschak-Carey, MSN, CDE2; Robert I. Berkowitz, MD3; Gary Foster, PhD1; Henry Glick, PhD3; Shiriki Kumanyika, PhD RD, MPH2; Yulisil Bell, BA; Raymond Carvajal, PsyD; Helen Chomen-towski; Renee Davenport; Lucy Faulconbridge, PhD; Louise Hesson, MSN, CRNP; Sharon Leonard, RD; Monica Mullien, RD, MPH.

University of Pittsburgh: John M. Jakicic, PhD; David E. Kelley, MD1; Jacqueline Wescupe-Thobaben, RN, BS, CDE; Daniel Edmondowicz, MD1; Lin Ewing, PhD, RN2; Andrea Hergenroeder, PhD, PT, CCS; Mary L. Klem, PhD, MLIS1; Mary Korytkowski, MD3; Andrea Kisska, PhD2; Lewis H. Kuller, MD, DrPH3; Amy D. Rickman, PhD, RD, LDN1; Rose Salata, MD1; Monica E. Yamamoto, DrPH, RD, FADA3; Janet Bonk, RN, MPH; Susan Copelli, BS, CTR; Rebecca Danchenko, BS; Tammy DeBruce, BA; Barbara Elnyczky, David O. Garcia, PhD; George A. Grove, MD; Patricia H. Harper, MS, RD; Susan Harrier, BS; Diane Heidingsfelder, MS, RD, CDE, LDN; Nicole H. Helbling, MS, RN; Diane Ives, MPH; Janet Krulka, RN, BS, CDE; Julie Mancino, MS, RD, CDE, LDN; Anne Mathews, PhD, RD, LDN; Lisa Martich, BS, CDE; Meghan McGuire, MS; Tracey J. Murray, BS; Anna Peluso, MS; Karen Quirin; Jennifer Rush, MPH; Joan R. Ritchea; Linda Semler, MS, RD, LDN; Karen Vujevich, RN, BC; MSN, CRNP; Kathy Williams, RN, MHA; Donna L. Wolf, PhD.

The Miriam Hospital/Brown Medical School: Rena R. Wing, PhD1; Renee Bright, MS1; Vincent Peria, MD, RD; Deborah Tate, PhD1; Amy Gorin, PhD2; Kara Gallagher, PhD2; Amy Bach, PhD; Barbara Bancroft, RN, MS; Anna Bertorelli, MBA, RD; Richard Carey, BS; Tatum Charron, BS; Heather Chenoit, MS; Kimberley Chula-Maguire, MS; Pamela Coward, MS, RD; Lisa Cronkite, BS;
Julie Currin, MD; Maureen Daly, RN; Caitlin Egan, MS; Erica Ferguson, BS, RD; Linda Foss, MPH; Jennifer Gauvin, BS; Don Kieffer, PhD; Lauren Lessard, BS; Deborah Maier, MS; JP Massaro, BS; Tammy Monk, MS; Rob Nicholson, PhD; Erin Patterson, BS; Suzanne Phelan, PhD; Hollie Raynor, PhD, RD; Douglas Raynor, PhD; Natalie Robinson, MS, RD; Deborah Robles; Jane Tavares, BS.

The University of Texas Health Science Center at San Antonio: Helen P. Nazuda, PhD; Maria G. Monteiz, RN, MSHP, CDE; Carlos Lorenzo, MD; Charles F. Coleman, MS; RD; Domingo Granado, RN; Kathly Hathaway, MS, RD; Juan Carlos Isaac, RC, BSN; Nora Ramirez, RN, BSN.

VA Puget Sound Health Care System/University of Washington: Steven E. Kahn, MB, ChB; Anne Kure, BS; Edward J. Boyko, MD, MPH; Edward Lipkin, MD, PhD; Dace Trence, MD; Subbulaxmi Trikudanathan, MD, MRCGP, MMSc; Elaine Tsai, MD; BD; Brenda Montgomery, RN, MS, CDE; Ivy Morgan-Taggart; Jolanta Socha, BS; Lonness Taylor, RN, BS; Alan Wesley, BA.

Southwestern American Indian Center, Phoenix, Arizona and Shippock, New Mexico: Subbulaxmi Trikudanathan, MD, MRCP, MMSc; Elaine Tsai, MD; BD; Brenda Montgomery, RN, MS, CDE; Ivy Morgan-Taggart; Jolanta Socha, BS; Lonness Taylor, RN, BS; Alan Wesley, BA.

The University of Southern California: Anne Peters, MD; Siran Ghazarian, MD; Elizabeth Beale, MD; Kati Konesman, RD, CDE; Brenda Quintero-Varela; Edgar Ramirez; Gabriela Rios, RD; Gabriela Rodriguez, MA; Valerie Ruelas MSW, LCSW; Sara Serafin-Dokhan; Martha Walker, RD.

Coordinating center Wake Forest University: Mark A. Espeland, PhD; Judy L. Bahnson, BA, CCRP; Lynne E. Wagenknecht, DrPH; David Reboussin, PhD; W. Jack Rejeski, PhD; Alain G. Bertiorni, MD, MPH; Wei Lang, PhD; David Leffkowitz, MD; Patrick S. Reynolds, MD; Denise Houston, PhD; Mike E. Miller, PhD; Laura D. Baker, PhD; Nicholas Paiement, PhD; Stephen R. Rapp, PhD; Stephen Kritchevsky, PhD; Haiying Chen, PhD, MM; Valerie Wilson, MD; Delia S. West, PhD; Ron Prineas, MD; Tandaw Samdarshi, MD; Amelia Hodges, BS, CCRP; Karen Wall; Carrie C. Anderson, MA, CCRP; Andrea Anderson, MS; Jerry M. Barnes, MA; Tara D. Becker; Delligah R. Cook; Valery S. Effoe, MD, MS; Melanie Franks, BBA; Katie Garcia, MS; Sarah A. Gaussoin, MS; Candace Goode; Michelle Gordon, MS; Lea Harvin, BS; Mary A. Hontz, BA; Don G. Hire, BS; Patricia Hogg, MS; Mark King, BS; Kathy Lane, BS; Rebecca H. Nielberg, MS; Julia T. Rushing, MS; Debbie Maier, MS; Jenny Walker, MS; Michael P. Walkup, MS.

Central resources centers

Central Laboratory, Northwest Lipid Metabolism and Diabetes Research Laboratories: Santica M. Marcovina, PhD, ScD; Jessica Hurtig; John J. Albers, PhD; Vinod Gaur, PhD.

ECG Reading Center, EPICARE, Wake Forest University School of Medicine: Elsayed Z. Soliman MD, MSc, MS; Charles Campbell; Zhu-Ming Zhang, MD; Mary Barr; Susan Hensley; Julie Hu; Lisa Keasler; Yabing Li, MD.
13. Søgaard AJ, Meyer HE, Ahmed LA, et al. Does recalled dieting increase the risk of non-vertebral osteoporotic fractures? The Tromso Study. Osteoporos. Int. 2012;23(12):2833–43.

14. Ryan DH, Espeland MA, Foster GD, et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003;24(5):610–28.

15. Bray G, Gregg E, Haffner S, et al. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diab Vasc Dis Res. 2006;3(3):202–15.

16. Beavers KM, Neiberg RH, Houston DK, et al. Body weight dynamics following intentional weight loss and physical performance: the Look AHEAD Movement and Memory Study. Obes Sci Pract. 2015;1(1):12–22.

17. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–38.

18. Compston JE, Laskey MA, Croucher PL, Coxon A, Kreitzman S. Effect of diet-induced weight loss on total body bone mass. Clin Sci (Lond). 1992;82(4):429–32.

19. Jensen LB, Quaade F, Sørensen OH. Bone loss accompanying voluntary weight loss in obese humans. J Bone Miner Res. 1994;9(4):459–63.

20. Villareal DT, Fontana L, Das SK, et al. Effect of two-year caloric restriction on bone metabolism and bone mineral density in non-obese younger adults: a randomized clinical trial. J Bone Miner Res. 2016;31(1):40–51.